New partnership looks to advance regenerative medicine outcomes for patients

1 Minute Read

Wake Forest Institute for Regenerative Medicine (WFIRM) recently announced a new partnership with MIMEDX, an industry leader in using amniotic tissue as a platform for regenerative medicine.

Located in the Innovation Quarter, WFIRM is recognized as an international leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans.

The new collaborative agreement between WFIRM and MIMEDX will help facilitate and validate new approaches to therapies and treatments.

“Regenerative medicine has captured the imagination of physicians and scientists worldwide, and inspires hope in patients looking for additional treatment options,” said Anthony Atala, M.D., Chair and Director of WFIRM. “I am eager to work with Tim Wright and his management team, and applaud the transformational progress they have made to strategically position MIMEDX for the future.”

Over 400 people at the institute, the largest in the world, work on more than 40 different tissues and organs. A number of the basic principles of tissue engineering and regenerative medicine were first developed at WFIRM, where researchers have successfully engineered replacement tissues and organs in all four categories – flat structures, tubular tissues, hollow organs and solid organs – and 15 different applications of cell/tissue therapy technologies, such as skin, urethras, cartilage, bladders, muscle, kidney, and vaginal organs, have been successfully used in human patients.